AIM Vaccine Co., Ltd. (HKG:6660)

Market Cap	4.45B
Revenue (ttm)	1.37B
Net Income (ttm)	-295.02M
Shares Out	1.23B
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	572.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	596,200
Average Volume	1,908,251
Open	3.630
Previous Close	3.630
Day's Range	3.580 - 3.740
52-Week Range	3.030 - 15.480
Beta	0.15
RSI	43.60
Earnings Date	May 29, 2025

About AIM Vaccine

AIM Vaccine Co., Ltd. researches, develops, manufactures, and commercializes of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, that is in phase III clinical trials indicated for meningococcal disease 13-Valent pneumonia Conjugate and 23-valent pneumonia Polysaccharide vaccine to treat pneumonia; and iterative serum-free rabies vaccine. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, that is in phase II trials fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 1,535
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6660

Financial Performance

In 2024, AIM Vaccine's revenue was 1.29 billion, an increase of 8.22% compared to the previous year's 1.19 billion. Losses were -277.23 million, -78.69% less than in 2023.

Financial numbers in CNY